DK1185253T3 - Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac - Google Patents

Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac

Info

Publication number
DK1185253T3
DK1185253T3 DK00942052T DK00942052T DK1185253T3 DK 1185253 T3 DK1185253 T3 DK 1185253T3 DK 00942052 T DK00942052 T DK 00942052T DK 00942052 T DK00942052 T DK 00942052T DK 1185253 T3 DK1185253 T3 DK 1185253T3
Authority
DK
Denmark
Prior art keywords
diclofenac
tramadol
administration
oral preparation
solid combination
Prior art date
Application number
DK00942052T
Other languages
Danish (da)
English (en)
Inventor
Johannes Bartholomaeus
Iris Ziegler
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7911586&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1185253(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Application granted granted Critical
Publication of DK1185253T3 publication Critical patent/DK1185253T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK00942052T 1999-06-17 2000-06-13 Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac DK1185253T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19927689A DE19927689A1 (de) 1999-06-17 1999-06-17 Orale Darreichungsformen zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
PCT/EP2000/005386 WO2000078294A2 (de) 1999-06-17 2000-06-13 Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac

Publications (1)

Publication Number Publication Date
DK1185253T3 true DK1185253T3 (da) 2004-04-05

Family

ID=7911586

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00942052T DK1185253T3 (da) 1999-06-17 2000-06-13 Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac

Country Status (15)

Country Link
US (1) US20020156133A1 (enExample)
EP (1) EP1185253B1 (enExample)
JP (1) JP4889897B2 (enExample)
AT (1) ATE260650T1 (enExample)
AU (1) AU778151B2 (enExample)
CA (1) CA2377174C (enExample)
DE (2) DE19927689A1 (enExample)
DK (1) DK1185253T3 (enExample)
ES (1) ES2215680T3 (enExample)
HK (1) HK1045113A1 (enExample)
HU (1) HUP0201687A3 (enExample)
MX (1) MXPA01013046A (enExample)
NZ (1) NZ516593A (enExample)
PT (1) PT1185253E (enExample)
WO (1) WO2000078294A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10108122A1 (de) 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
EP1628685B1 (en) 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
WO2006110157A2 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
CN101257894A (zh) 2005-07-07 2008-09-03 法纳姆公司 高水溶性药物的缓释药物组合物
US20070009591A1 (en) * 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
EP1785412A1 (en) * 2005-11-14 2007-05-16 IPCA Laboratories Limited Tramadol recovery process
DE102006006532B4 (de) * 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
DK2018160T3 (da) 2006-03-16 2012-02-06 Tris Pharma Inc Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser
JP2008208078A (ja) * 2007-02-27 2008-09-11 Takada Seiyaku Kk 分割錠剤
HRP20120700T1 (hr) 2008-07-08 2012-09-30 Gilead Sciences SOLI SPOJEVA INHIBITORA HIV-a
DE102008056312A1 (de) 2008-11-07 2010-05-12 Biogenerics Pharma Gmbh Verwendung von Mikrotabletten als Lebens-und Futtermittelzusatz
KR20130129070A (ko) * 2010-07-12 2013-11-27 융신 파마슈티칼 인더스트리얼 컴파니 리미티드 트라마돌의 디클로페낙 염
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
CA2880456A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
CN110755396B (zh) * 2019-12-06 2022-04-08 北京悦康科创医药科技股份有限公司 一种布洛芬缓释小丸及其制备方法
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
AU661723B2 (en) * 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5919826A (en) * 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel

Also Published As

Publication number Publication date
NZ516593A (en) 2003-08-29
ATE260650T1 (de) 2004-03-15
CA2377174C (en) 2009-07-28
EP1185253B1 (de) 2004-03-03
DE19927689A1 (de) 2000-12-21
DE50005529D1 (de) 2004-04-08
ES2215680T3 (es) 2004-10-16
WO2000078294A2 (de) 2000-12-28
WO2000078294A3 (de) 2001-03-29
AU778151B2 (en) 2004-11-18
MXPA01013046A (es) 2002-06-04
CA2377174A1 (en) 2000-12-28
PT1185253E (pt) 2004-07-30
JP2003502360A (ja) 2003-01-21
US20020156133A1 (en) 2002-10-24
HUP0201687A2 (en) 2002-09-28
JP4889897B2 (ja) 2012-03-07
HK1045113A1 (zh) 2002-11-15
HUP0201687A3 (en) 2005-07-28
AU5680500A (en) 2001-01-09
EP1185253A2 (de) 2002-03-13

Similar Documents

Publication Publication Date Title
DK1185253T3 (da) Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
NO20014035L (no) System for oral administrasjon av medikament
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
DK1202965T3 (da) Indolderivater, fremgangsmåde til fremstilling deraf, farmaceutiske præparater indeholdende disse og deres medicinske anvendelse
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
NO20024891D0 (no) Farmasöytiske sammensetninger
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
NO20006138D0 (no) Substituerte indolinoner, fremstilling og anvendelse derav som medikamenter
ATE354362T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
DK1417206T3 (da) Hidtil ukendte 2H-pyridazin-3-on-derivater, farmaceutiske præparater indeholdende det samme, og en fremgangsmåde til fremstilling af den aktive bestanddel
NO984290L (no) Farmas°ytisk nyttige forbindelser
SE0102843D0 (sv) Stabilized oral pharmaceutical composition containing lodide and lodate and method
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
DE602004005564D1 (de) Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten
DK1121127T3 (da) Orale farmaceutiske sammensætninger, som indeholder buprenorphin
NO20013060L (no) Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
NO20064808L (no) Orale matrixformuleringer med licarbazepin
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.